🇺🇸 Degludec insulin in United States

8 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Myocardial Infarction — 1 report (12.5%)
  2. Cardiac Arrest — 1 report (12.5%)
  3. Chronic Kidney Disease — 1 report (12.5%)
  4. Diarrhoea — 1 report (12.5%)
  5. Electrocardiogram Qt Prolonged — 1 report (12.5%)
  6. Mineral Metabolism Disorder — 1 report (12.5%)
  7. Torsade De Pointes — 1 report (12.5%)
  8. Weight Decreased — 1 report (12.5%)

Source database →

Degludec insulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Degludec insulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Degludec insulin in United States?

King Faisal Specialist Hospital & Research Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.